These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34558772)

  • 1. The use of uncertain exposure-A method to define switching and add-on in pharmacoepidemiology.
    Pazzagli L; Linder M; Reutfors J; Brandt L
    Pharmacoepidemiol Drug Saf; 2022 Jan; 31(1):28-36. PubMed ID: 34558772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical approaches to minimizing immeasurable time bias in cohort studies.
    Oh IS; Baek YH; Jeong HE; Filion KB; Shin JY
    Int J Epidemiol; 2021 Jul; 50(3):987-999. PubMed ID: 33367629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited impact of drug exposure misclassification from non-benefit thiazolidinedione drug use on mortality and hospitalizations from Saskatchewan, Canada: a cohort study.
    Gamble JM; Johnson JA; McAlister FA; Majumdar SR; Simpson SH; Eurich DT
    Clin Ther; 2015 Mar; 37(3):629-42. PubMed ID: 25596665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?
    Palmaro A; Boucherie Q; Dupouy J; Micallef J; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):544-553. PubMed ID: 28266748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An empirical assessment of immeasurable time bias in the setting of nested case-control studies: Statins and all-cause mortality among patients with heart failure.
    Oh IS; Filion KB; Jeong HE; Shin JY
    Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1318-1327. PubMed ID: 31432599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.
    Weberpals J; Jansen L; van Herk-Sukel MPP; Kuiper JG; Aarts MJ; Vissers PAJ; Brenner H
    Eur J Epidemiol; 2017 Nov; 32(11):1019-1031. PubMed ID: 28864947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of methods to control for immortal time bias in a pharmacoepidemiologic analysis of renin-angiotensin system inhibitors in type 2 diabetes.
    Yang X; Kong AP; Luk AO; Ozaki R; Ko GT; Ma RC; Chan JC; So WY
    J Epidemiol; 2014; 24(4):267-73. PubMed ID: 24747198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-related biases in pharmacoepidemiology.
    Suissa S; Dell'Aniello S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1101-1110. PubMed ID: 32783283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors.
    Jacobus S; Schneeweiss S; Chan KA
    Pharmacoepidemiol Drug Saf; 2004 Oct; 13(10):695-702. PubMed ID: 15386727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence.
    Hall GC; Lanes S; Bollaerts K; Zhou X; Ferreira G; Gini R
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1450-1455. PubMed ID: 32860317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and epidemiological considerations while constructing treatment episodes using observational data: A simulation study.
    Pazzagli L; Andersen M; Sessa M
    Pharmacoepidemiol Drug Saf; 2022 Jan; 31(1):55-60. PubMed ID: 34611960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core concepts in pharmacoepidemiology: Measurement of medication exposure in routinely collected healthcare data for causal inference studies in pharmacoepidemiology.
    Thai TN; Winterstein AG
    Pharmacoepidemiol Drug Saf; 2024 Mar; 33(3):e5683. PubMed ID: 37752827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration.
    Patrick AR; Schneeweiss S; Brookhart MA; Glynn RJ; Rothman KJ; Avorn J; Stürmer T
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):551-9. PubMed ID: 21394812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies.
    Stricker BH; Stijnen T
    Eur J Epidemiol; 2010 Apr; 25(4):245-51. PubMed ID: 20358262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: Empirical illustration using breast cancer recurrence.
    Chen Y; Wang J; Chubak J; Hubbard RA
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):264-268. PubMed ID: 30375122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults.
    Varga S; Alcusky M; Keith SW; Hegarty SE; Del Canale S; Lombardi M; Maio V
    Br J Clin Pharmacol; 2017 Nov; 83(11):2572-2580. PubMed ID: 28667818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Drug Exposure Definitions on Observed Associations in Pharmacoepidemiology Research.
    Eskin M; Eurich DT; Simpson SH
    J Popul Ther Clin Pharmacol; 2018 Mar; 25(1):e39-e52. PubMed ID: 29949683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure.
    Daniel S; Koren G; Lunenfeld E; Levy A
    Am J Obstet Gynecol; 2015 Mar; 212(3):307.e1-6. PubMed ID: 25265406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
    Luijken K; Spekreijse JJ; van Smeden M; Gardarsdottir H; Groenwold RHH
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):960-974. PubMed ID: 33899305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for time-varying exposure related problems in pharmacoepidemiology: An overview.
    Pazzagli L; Linder M; Zhang M; Vago E; Stang P; Myers D; Andersen M; Bahmanyar S
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):148-160. PubMed ID: 29285840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.